Adventis Group PLC
04 November 2004
Adventis Group plc
Adventis Group plc announces potential acquisition of pharmaceutical advertising
agency
4th November 2004
Adventis Group plc ('Adventis'), the specialist multimedia and marketing agency,
is pleased to announce that it is in the final stages of negotiations to acquire
a pharmaceutical advertising agency. Further information with regard to the
transaction will be announced in due course. Adventis floated on AIM in July
2004 in a placing that raised £3.6m gross to fund, amongst other things, a
strategy of growth by strategic acquisitions and joint ventures.
Charles Phillpot, CEO of Adventis commented, 'As stated at the time of our
floatation we stated our intention to make appropriate acquisitions in key
markets. We have assessed several candidates within the pharmaceutical industry
and have now entered the final stages of negotiations with our chosen partner.'
Enquiries
Charles Phillpot, Managing Director Sarah Gestetner, Fiona Bradshaw, Fiona Mulcahy
Adventis Group plc Citigate Dewe Rogerson
Tel: 020 7034 4750 Tel: 020 7638 9571
Paul Dudley
WH Ireland Limited
Tel: 020 7397 3225
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.